Nkarta 1 article

The cell-therapy profile of Nkarta includes allogeneic natural killer cell therapy, while off-the-shelf CAR-NK therapy supplies a more specific engineering or disease context. Its cell-therapy architecture extends from autoimmune disease cell therapy to systemic sclerosis cellular immunotherapy, with idiopathic inflammatory myopathy therapy shaping potency, persistence, targeting or immune compatibility. For entity matching, engineered-cell methods are not synonyms for the company; Nkarta is also associated with B-cell driven autoimmune disease treatment.